Zenagamtide vs Cagrilintide
Both involve amylin-family biology but zenagamtide is a unimolecular GLP-1/amylin/calcitonin receptor agonist while cagrilintide is a long-acting amylin analogue; evidence maturity differs.
| Attribute | Zenagamtide | Cagrilintide |
|---|---|---|
| Human evidence | Two peer-reviewed 2026 Phase II trials show significant HbA1c reductions with subcutaneous and oral zenagamtide in type 2 diabetes; Phase 3 weight-management development is underway. | Cagrilintide has randomized Phase II evidence and a Phase IIIa monotherapy arm within REDEFINE 1; the dedicated RENEW Phase 3 monotherapy programme is underway. |
| Research focus | Obesity, type 2 diabetes, sleep apnoea, knee osteoarthritis, heart failure | Obesity, appetite and weight-management research |
| Regulatory status | Investigational; Phase 3 obesity programme initiated in 2026. No general marketing authorisation identified. | FDA states cagrilintide is not a component of an FDA-approved drug, has not been found safe and effective for any condition, and cannot be used in U.S. compounding under federal law. |
| Route / formulation | Oral and subcutaneous regimens are formulation-specific and not interchangeable. | Trial evidence does not establish quality or equivalence of research-market material. |
Why these are compared
These compounds appear in the weight & appetite / amylin biology evidence landscape, but they are not interchangeable. Zenagamtide is unimolecular glp-1, amylin and calcitonin receptor agonist peptide studied in obesity, type 2 diabetes, sleep apnoea, knee osteoarthritis, heart failure; Cagrilintide is long-acting amylin analogue peptide studied in obesity, appetite and weight-management research. The purpose of this page is to compare the evidence base, not to recommend one compound over another.
Evidence maturity
Zenagamtide: Peer-reviewed Phase II evidence; Phase 3 development underway / investigational.
Cagrilintide: Phase 3 monotherapy evidence and development; investigational / not FDA-approved.
The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.
What this comparison can and cannot establish
No direct head-to-head trial identified. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty.